Datopotamab deruxtecan
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Jun 1, 2025 → Aug 1, 2027
NCT ID
NCT06676917About Datopotamab deruxtecan
Datopotamab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Non-small Cell Lung Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06676917. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06279728 | Pre-clinical | Completed |
| NCT06676917 | Phase 2 | Withdrawn |
| NCT06176261 | Phase 2 | Recruiting |
| NCT05866432 | Phase 2 | Recruiting |
Competing Products
20 competing products in Non-small Cell Lung Cancer